LEADER 01466nam  2200385Ia 450 
001 9910698127103321
005 20090324130955.0
035   $a(CKB)5470000002395712
035   $a(OCoLC)316867708
035   $a(EXLCZ)995470000002395712
100   $a20090324d2008      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $econtents of a complete submission for the evaluation of proprietary names
210  1$aSilver Spring, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) ;$aRockville, MD :$cCenter for Biologics Evaluation and Research (CBER),$d[2008]
215   $ai, 17 pages $cdigital, PDF file
300   $aTitle from PDF title page (viewed on Mar. 24, 2009).
300   $a"Draft guidance."
300   $a"November 2008."
517   $aGuidance for industry 
606   $aDrugs$xLabeling$xEvaluation
606   $aBrand name products$xEvaluation
615  0$aDrugs$xLabeling$xEvaluation.
615  0$aBrand name products$xEvaluation.
712 02$aCenter for Drug Evaluation and Research (U.S.)
712 02$aCenter for Biologics Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910698127103321
996   $aGuidance for industry$93434577
997   $aUNINA